VYNE Therapeutics to merge with Yarrow Bioscience.

VYNE Therapeutics, a biotechnology company that focuses on developing novel therapeutics, agreed to merge with Yarrow Bioscience, a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. Financial terms were not disclosed. “We are excited about this merger, which establishes Yarrow on a strong foundation to advance YB-101 for patients living with Graves’ disease and thyroid eye disease. Autoimmune thyroid disorders represent areas of significant unmet need, and we believe YB-101 has the potential to deliver meaningful clinical benefit through its highly targeted TSHR-directed mechanism of action. Together with an exceptional leadership team and the support of a premier group of life sciences investors, Yarrow is well positioned to deliver on our mission to transform treatment options in this field,” Rebecca Frey, Pharm.D., Yarrow President and CEO.